Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.14
ESRX's Cash-to-Debt is ranked lower than
89% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. ESRX: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
ESRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.31 Max: No Debt
Current: 0.14
0.09
No Debt
Equity-to-Asset 0.33
ESRX's Equity-to-Asset is ranked lower than
63% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. ESRX: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
ESRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.33 Max: 0.65
Current: 0.33
0.13
0.65
Debt-to-Equity 0.88
ESRX's Debt-to-Equity is ranked lower than
84% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.59 vs. ESRX: 0.88 )
Ranked among companies with meaningful Debt-to-Equity only.
ESRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.29  Med: 0.88 Max: 3.27
Current: 0.88
0.29
3.27
Debt-to-EBITDA 2.18
ESRX's Debt-to-EBITDA is ranked lower than
56% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.82 vs. ESRX: 2.18 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ESRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.08  Med: 2.3 Max: 3.39
Current: 2.18
1.08
3.39
Interest Coverage 9.04
ESRX's Interest Coverage is ranked lower than
52% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.81 vs. ESRX: 9.04 )
Ranked among companies with meaningful Interest Coverage only.
ESRX' s Interest Coverage Range Over the Past 10 Years
Min: 4.51  Med: 7.71 Max: 16.5
Current: 9.04
4.51
16.5
Piotroski F-Score: 7
Altman Z-Score: 3.17
Beneish M-Score: -2.54
WACC vs ROIC
7.34%
17.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.49
ESRX's Operating Margin % is ranked higher than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.49 vs. ESRX: 5.49 )
Ranked among companies with meaningful Operating Margin % only.
ESRX' s Operating Margin % Range Over the Past 10 Years
Min: 2.98  Med: 4.81 Max: 6.06
Current: 5.49
2.98
6.06
Net Margin % 4.51
ESRX's Net Margin % is ranked higher than
63% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.87 vs. ESRX: 4.51 )
Ranked among companies with meaningful Net Margin % only.
ESRX' s Net Margin % Range Over the Past 10 Years
Min: 1.4  Med: 2.7 Max: 4.51
Current: 4.51
1.4
4.51
ROE % 27.57
ESRX's ROE % is ranked higher than
85% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.89 vs. ESRX: 27.57 )
Ranked among companies with meaningful ROE % only.
ESRX' s ROE % Range Over the Past 10 Years
Min: 8.16  Med: 23.28 Max: 87.47
Current: 27.57
8.16
87.47
ROA % 8.73
ESRX's ROA % is ranked higher than
75% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.25 vs. ESRX: 8.73 )
Ranked among companies with meaningful ROA % only.
ESRX' s ROA % Range Over the Past 10 Years
Min: 3.3  Med: 7.51 Max: 14.42
Current: 8.73
3.3
14.42
ROC (Joel Greenblatt) % 426.87
ESRX's ROC (Joel Greenblatt) % is ranked higher than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 65.45 vs. ESRX: 426.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ESRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 220.38  Med: 402.33 Max: 589.99
Current: 426.87
220.38
589.99
3-Year Revenue Growth Rate 8.90
ESRX's 3-Year Revenue Growth Rate is ranked higher than
61% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.60 vs. ESRX: 8.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ESRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 23.8 Max: 86.2
Current: 8.9
5.3
86.2
3-Year EBITDA Growth Rate 17.50
ESRX's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. ESRX: 17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ESRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 15  Med: 24.8 Max: 66
Current: 17.5
15
66
3-Year EPS without NRI Growth Rate 43.10
ESRX's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.70 vs. ESRX: 43.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ESRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 28.1 Max: 74.6
Current: 43.1
0
74.6
GuruFocus has detected 2 Warning Signs with Express Scripts Holding Co ESRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ESRX's 30-Y Financials

Financials (Next Earnings Date: 2018-04-24)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

ESRX Guru Trades in Q1 2017

Leucadia National 7,009 sh (New)
Seth Klarman 1,228,619 sh (New)
Donald Yacktman 15,200 sh (New)
Jeremy Grantham 3,700 sh (New)
Caxton Associates 7,100 sh (New)
First Pacific Advisors 33,700 sh (New)
Jim Simons 1,308,239 sh (+9353.28%)
Paul Tudor Jones 234,995 sh (+274.28%)
Ray Dalio 539,841 sh (+53.19%)
Dodge & Cox 28,800,496 sh (+35.99%)
Steven Cohen 703,500 sh (+32.01%)
Mario Gabelli 14,990 sh (+26.18%)
Joel Greenblatt 1,160,566 sh (+12.64%)
Charles Brandes 2,392,377 sh (+9.45%)
Barrow, Hanley, Mewhinney & Strauss 17,612,834 sh (+4.16%)
David Dreman 8,837 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Robert Olstein Sold Out
Jeff Auxier 84,955 sh (-0.05%)
Chris Davis 4,257,264 sh (-1.34%)
Ken Fisher 346,040 sh (-2.01%)
Manning & Napier Advisors, Inc 2,699,087 sh (-14.64%)
Glenn Greenberg 1,413,775 sh (-25.17%)
David Rolfe 92,675 sh (-94.64%)
» More
Q2 2017

ESRX Guru Trades in Q2 2017

Richard Pzena 2,838,878 sh (New)
Ronald Muhlenkamp 61,979 sh (New)
Seth Klarman 2,556,891 sh (+108.11%)
David Dreman 15,063 sh (+70.45%)
Dodge & Cox 36,188,517 sh (+25.65%)
First Pacific Advisors 40,000 sh (+18.69%)
Barrow, Hanley, Mewhinney & Strauss 20,307,241 sh (+15.30%)
Ray Dalio 612,525 sh (+13.46%)
Donald Yacktman 15,200 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
Leucadia National Sold Out
Jim Simons Sold Out
Glenn Greenberg Sold Out
Caxton Associates Sold Out
Steven Cohen Sold Out
Jeff Auxier 84,712 sh (-0.29%)
Mario Gabelli 14,760 sh (-1.53%)
Ken Fisher 339,085 sh (-2.01%)
Chris Davis 4,011,191 sh (-5.78%)
Charles Brandes 2,233,243 sh (-6.65%)
Jeremy Grantham 3,200 sh (-13.51%)
Manning & Napier Advisors, Inc 2,212,332 sh (-18.03%)
David Rolfe 63,850 sh (-31.10%)
Joel Greenblatt 682,163 sh (-41.22%)
Paul Tudor Jones 22,465 sh (-90.44%)
» More
Q3 2017

ESRX Guru Trades in Q3 2017

Diamond Hill Capital 3,253 sh (New)
Caxton Associates 3,300 sh (New)
Paul Tudor Jones 44,496 sh (+98.07%)
First Pacific Advisors 54,100 sh (+35.25%)
Joel Greenblatt 865,757 sh (+26.91%)
Richard Pzena 3,509,800 sh (+23.63%)
Ken Fisher 349,564 sh (+3.09%)
Donald Yacktman 15,200 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
Seth Klarman 2,556,891 sh (unchged)
David Dreman 15,063 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Jeremy Grantham Sold Out
Jeff Auxier 84,557 sh (-0.18%)
Ronald Muhlenkamp 61,215 sh (-1.23%)
Ray Dalio 596,933 sh (-2.55%)
Dodge & Cox 34,938,393 sh (-3.45%)
Chris Davis 3,848,419 sh (-4.06%)
Manning & Napier Advisors, Inc 2,058,410 sh (-6.96%)
Barrow, Hanley, Mewhinney & Strauss 18,704,089 sh (-7.89%)
Mario Gabelli 11,940 sh (-19.11%)
Charles Brandes 1,675,423 sh (-24.98%)
David Rolfe 46,900 sh (-26.55%)
» More
Q4 2017

ESRX Guru Trades in Q4 2017

Pioneer Investments 627,178 sh (New)
Leucadia National 7,597 sh (New)
Glenn Greenberg 7,080 sh (New)
Jeff Ubben 1,200,000 sh (New)
Richard Pzena 3,602,780 sh (+2.65%)
Charles Brandes 1,718,420 sh (+2.57%)
Chris Davis 3,916,700 sh (+1.77%)
Jeff Auxier 84,874 sh (+0.37%)
Donald Yacktman 15,200 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
David Dreman 15,063 sh (unchged)
Steven Cohen 138,100 sh (unchged)
Caxton Associates Sold Out
Dodge & Cox 34,767,794 sh (-0.49%)
Ronald Muhlenkamp 60,439 sh (-1.27%)
Diamond Hill Capital 3,207 sh (-1.41%)
Mario Gabelli 11,200 sh (-6.20%)
Barrow, Hanley, Mewhinney & Strauss 17,095,646 sh (-8.60%)
Seth Klarman 2,306,456 sh (-9.79%)
Paul Tudor Jones 39,962 sh (-10.19%)
Ken Fisher 302,322 sh (-13.51%)
David Rolfe 40,400 sh (-13.86%)
Joel Greenblatt 710,916 sh (-17.89%)
First Pacific Advisors 6,250 sh (-88.45%)
Ray Dalio 23,259 sh (-96.10%)
» More
» Details

Insider Trades

Latest Guru Trades with ESRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-12-31 Reduce -0.49%0.01%$56.81 - $74.99 $ 75.2718%34,767,794
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Reduce -8.60%0.15%$56.81 - $74.99 $ 75.2718%17,095,646
Chris Davis 2017-12-31 Add 1.77%0.02%$56.81 - $74.99 $ 75.2718%3,916,700
Richard Pzena 2017-12-31 Add 2.65%0.03%$56.81 - $74.99 $ 75.2718%3,602,780
Seth Klarman 2017-12-31 Reduce -9.79%0.2%$56.81 - $74.99 $ 75.2718%2,306,456
Charles Brandes 2017-12-31 Add 2.57%0.06%$56.81 - $74.99 $ 75.2718%1,718,420
Joel Greenblatt 2017-12-31 Reduce -17.89%0.14%$56.81 - $74.99 $ 75.2718%710,916
Ken Fisher 2017-12-31 Reduce -13.51%$56.81 - $74.99 $ 75.2718%302,322
Ronald Muhlenkamp 2017-12-31 Reduce -1.27%0.02%$56.81 - $74.99 $ 75.2718%60,439
Mario Gabelli 2017-12-31 Reduce -6.20%$56.81 - $74.99 $ 75.2718%11,200
Leucadia National 2017-12-31 New Buy0.04%$56.81 - $74.99 $ 75.2718%7,597
Glenn Greenberg 2017-12-31 New Buy0.02%$56.81 - $74.99 $ 75.2718%7,080
Dodge & Cox 2017-09-30 Reduce -3.45%0.07%$60.3 - $63.92 $ 75.2721%34,938,393
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -7.89%0.16%$60.3 - $63.92 $ 75.2721%18,704,089
Chris Davis 2017-09-30 Reduce -4.06%0.05%$60.3 - $63.92 $ 75.2721%3,848,419
Richard Pzena 2017-09-30 Add 23.63%0.22%$60.3 - $63.92 $ 75.2721%3,509,800
Charles Brandes 2017-09-30 Reduce -24.98%0.56%$60.3 - $63.92 $ 75.2721%1,675,423
Joel Greenblatt 2017-09-30 Add 26.91%0.17%$60.3 - $63.92 $ 75.2721%865,757
Ken Fisher 2017-09-30 Add 3.09%$60.3 - $63.92 $ 75.2721%349,564
Ronald Muhlenkamp 2017-09-30 Reduce -1.23%0.02%$60.3 - $63.92 $ 75.2721%61,215
Mario Gabelli 2017-09-30 Reduce -19.11%$60.3 - $63.92 $ 75.2721%11,940
Dodge & Cox 2017-06-30 Add 25.65%0.4%$59.26 - $67.25 $ 75.2720%36,188,517
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Add 15.30%0.26%$59.26 - $67.25 $ 75.2720%20,307,241
Chris Davis 2017-06-30 Reduce -5.78%0.07%$59.26 - $67.25 $ 75.2720%4,011,191
Richard Pzena 2017-06-30 New Buy0.99%$59.26 - $67.25 $ 75.2720%2,838,878
Seth Klarman 2017-06-30 Add 108.11%0.98%$59.26 - $67.25 $ 75.2720%2,556,891
Charles Brandes 2017-06-30 Reduce -6.65%0.16%$59.26 - $67.25 $ 75.2720%2,233,243
Joel Greenblatt 2017-06-30 Reduce -41.22%0.4%$59.26 - $67.25 $ 75.2720%682,163
Ken Fisher 2017-06-30 Reduce -2.01%$59.26 - $67.25 $ 75.2720%339,085
Ronald Muhlenkamp 2017-06-30 New Buy1.24%$59.26 - $67.25 $ 75.2720%61,979
David Dreman 2017-06-30 Add 70.45%0.22%$59.26 - $67.25 $ 75.2720%15,063
Mario Gabelli 2017-06-30 Reduce -1.53%$59.26 - $67.25 $ 75.2720%14,760
Glenn Greenberg 2017-06-30 Sold Out 4.45%$59.26 - $67.25 $ 75.2720%0
Leucadia National 2017-06-30 Sold Out 0.04%$59.26 - $67.25 $ 75.2720%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 446110    SIC: 5912
Compare:NYSE:CI, NYSE:HUM, NYSE:AET, NYSE:ANTM, NYSE:CNC, NYSE:CVS, NYSE:WCG, NYSE:MOH, NAS:MGLN, BSP:ODPV3, BSP:QUAL3, XPAR:GDS, NAS:HIIQ, OSTO:MCOV B, ROCO:6665, ATH:IATR, ASX:ONT, TSXV:NAC, MIL:HI, OSTO:FEEL » details
Traded in other countries:ESRX.Austria, ESRX34.Brazil, 4XS.Germany, ESRX.Mexico, ESRX.Switzerland, 0R0W.UK,
Headquarter Location:USA
Express Scripts Holding Co is a pharmacy benefit manager in the United States. It offers healthcare management and administration services such as managed care organizations, health insurers, workers' compensation plans and government health programs.

Express Scripts is the largest pharmacy benefit manager in the United States. Through its mail-order pharmacy and network of retail pharmacies, Express Scripts processes approximately 1.3 billion adjusted prescriptions annually for its payer clients.

Guru Investment Theses on Express Scripts Holding Co

Jeff Auxier Comments on Express Scripts - Feb 06, 2018

Express Scripts (NASDAQ:ESRX) recently acquired eviCore Healthcare, an industry leader in evidence-based medical benefit management services. EviCore helps manage medical benefits for 100 million people, and Express Scripts expects the acquisition to be accretive to adjusted diluted earnings per share in 2018, which they now estimate in the range of $7.67 to $7.87. At a P/E of 12 times 2018 the stock seems very cheap.







From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Weitz Funds Comments on Express Scripts - Jan 26, 2017

Express Scripts (NASDAQ:ESRX) is the largest stand-alone pharmacy benefits manager (PBM) in the U.S., helping health benefit providers improve access to (and the affordability of) prescription drugs. The ongoing impasse with its largest customer (Anthem), an evolving competitive landscape, and public finger pointing between so-called middlemen and drug manufacturers as to the source of persistent drug inflation led us to (once again) test the assumptions underlying our notion of Express’s business value. Our additional diligence suggested an increased probability of Anthem not renewing with Express Scripts in 2019. In addition, the likelihood that competitive or industry pressures offset a portion (potentially even all) of other future profit-per-script drivers seem to have increased, particularly for Express. This combination made the risk-reward trade-off less compelling, and we elected to close our position in Express across the funds following the post-election rally in November.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Express Scripts - Nov 11, 2016

Express Scripts (NASDAQ:ESRX) is the largest independent pharmacy benefits manager (PBM) in the United States, helping health benefit providers improve access to (and the affordability of) prescription drugs. As the U.S. election enters its final stages, pharmaceutical manufacturers have shouldered a significant portion of the public’s frustration with the growing lack of affordability in healthcare. In recent weeks, several drug companies have attempted to shift the conversation by pointing fingers at PBMs and other “middlemen” as contributing to (as opposed to minimizing) rising prescription drug costs. Express Scripts and its peers provide a necessary and valuable service to plan sponsors, constructing custom plan designs that balance customer desires for access, cost and flexibility. Providing the absolute lowest cost for each drug utilized is not often the sponsor’s only (or even primary) goal. Additionally, competitive intensity across the industry is high, with no less than two (and in most cases three) potential PBM models to choose from for managing drug costs. We believe Express Scripts keeps a reasonable amount of the savings it generates for clients (we estimate between 10-15%) and that demand for its services will remain high as cost challenges persist. Express Scripts’ shares currently trade at a meaningful discount to our estimate of intrinsic value.



  • From Weitz Balanced Fund third quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Express Scripts - Nov 08, 2016

QVC Group (NASDAQ:QVCA) is owned by Liberty Interactive. QVC is an American television network and multinational corporation specializing in televised and online shopping experiences. Shares of QVC Group fell after management indicated that its U.S. business had experienced significant sales headwinds, which are likely to continue into the next quarter. QVC’s U.S. business, which has not seen a sales decline since the Great Recession, appears to be tracking down in the mid to high single- digits, as its fashion business has slowed and a large beauty vendor is dealing with customer complaints on its hair care products. Importantly, we don’t view these issues as a sign of the QVC model suddenly being broken. QVC’s customer retention and loyalty remain strong, as does viewership of their network. Additionally, the international businesses appear unaffected by the current U.S.-centric slowdown. Although the decline in QVC shares is disappointing, we believe management will take advantage, growing their per share business value by continuing to execute their share repurchase strategy.

From Wallace Weitz (Trades, Portfolio)'s Partners Value Fund third-quarter commentary.

Check out Wallace Weitz latest stock trades

David Rolfe Comments on Express Scripts - Jul 13, 2016

Express Scripts (NASDAQ:ESRX) was a top contributor during the quarter. The stock recovered some of the poor performance from the first quarter after Anthem management noted that, despite filing a lawsuit over Express Scripts’s pricing, they believed any ruling on the lawsuit would take several years and were still open to negotiations. Express Scripts is the sole, independent pharmacy benefits manager (PBM), which we think is key for maintaining their alignment with customers. We continue to expect Express Scripts to drive mid-to-high single-digit EBITDA growth using its scale to negotiate better pricing with drug manufacturers and service providers, while increasing patient adherence. We think earnings per share can continue to grow at a double-digit rate as shares are repurchased at what, in our view, are attractive valuations. That said, as shares rallied from their previous lows, we reduced the stock's weighting to better reflect the risk/reward of Express Scripts’s growth and valuation.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

Brandes Investments Comments on Express Scripts - Jun 15, 2016

Express Scripts (NASDAQ:ESRX) declined 20% during the quarter due to a dispute with its largest client, health insurer Anthem (which accounts for 15%-20% of Express Scripts’ sales), as Anthem believes that Express Scripts needs to pass on larger drug cost savings to its customers. Under the existing contract, Anthem is entitled to a good-faith repricing of the contract terms, the deadline for which was December 15, 2015. As the deadline has passed and Express Scripts still has not provided Anthem with an offer that Anthem deems acceptable, Anthem has recently decided to take legal action against Express Scripts. Express Scripts’ CEO stated the company intends to resolve the dispute and keep Anthem as a customer.



We believe the market has over-reacted to the dispute as the current valuation prices in more than a complete loss of the Anthem contract. While there are multiple possibilities, we believe the most likely outcome is a renegotiation to extend the contract, likely at a lower margin but with increased volumes due to Anthem’s acquisition of Cigna. However there is a risk that Anthem switches to another vendor or brings the business in-house, although it lacks scale relative to peers. Given that the market seems to have priced in the worst-case outcome, we continue to believe that Express Scripts offers an attractive margin of safety.



From Brandes' Global Equity Fund first quarter 2016 commentary.



Check out Charles Brandes latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 9.71
ESRX's PE Ratio is ranked higher than
95% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ESRX: 9.71 )
Ranked among companies with meaningful PE Ratio only.
ESRX' s PE Ratio Range Over the Past 10 Years
Min: 8.31  Med: 25.62 Max: 36.23
Current: 9.71
8.31
36.23
Forward PE Ratio 8.08
ESRX's Forward PE Ratio is ranked higher than
92% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.27 vs. ESRX: 8.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 9.71
ESRX's PE Ratio without NRI is ranked higher than
95% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ESRX: 9.71 )
Ranked among companies with meaningful PE Ratio without NRI only.
ESRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.31  Med: 25.41 Max: 35.5
Current: 9.71
8.31
35.5
Price-to-Owner-Earnings 8.80
ESRX's Price-to-Owner-Earnings is ranked higher than
94% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.47 vs. ESRX: 8.80 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ESRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.68  Med: 13.81 Max: 27.84
Current: 8.8
5.68
27.84
PB Ratio 2.34
ESRX's PB Ratio is ranked higher than
73% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.42 vs. ESRX: 2.34 )
Ranked among companies with meaningful PB Ratio only.
ESRX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 3.31 Max: 31.78
Current: 2.34
1.85
31.78
PS Ratio 0.44
ESRX's PS Ratio is ranked higher than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.73 vs. ESRX: 0.44 )
Ranked among companies with meaningful PS Ratio only.
ESRX' s PS Ratio Range Over the Past 10 Years
Min: 0.34  Med: 0.58 Max: 1.07
Current: 0.44
0.34
1.07
Price-to-Free-Cash-Flow 8.58
ESRX's Price-to-Free-Cash-Flow is ranked higher than
89% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.78 vs. ESRX: 8.58 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ESRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.7  Med: 13.24 Max: 25.56
Current: 8.58
5.7
25.56
Price-to-Operating-Cash-Flow 8.16
ESRX's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.15 vs. ESRX: 8.16 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ESRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.46  Med: 12.34 Max: 23.25
Current: 8.16
5.46
23.25
EV-to-EBIT 10.11
ESRX's EV-to-EBIT is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.89 vs. ESRX: 10.11 )
Ranked among companies with meaningful EV-to-EBIT only.
ESRX' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.2  Med: 15.6 Max: 30.2
Current: 10.11
8.2
30.2
EV-to-EBITDA 7.63
ESRX's EV-to-EBITDA is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.81 vs. ESRX: 7.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.7 Max: 22.4
Current: 7.63
6.1
22.4
EV-to-Revenue 0.56
ESRX's EV-to-Revenue is ranked higher than
67% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. ESRX: 0.56 )
Ranked among companies with meaningful EV-to-Revenue only.
ESRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.7 Max: 1.2
Current: 0.56
0.4
1.2
PEG Ratio 0.63
ESRX's PEG Ratio is ranked higher than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.63 )
Ranked among companies with meaningful PEG Ratio only.
ESRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.43  Med: 1.02 Max: 1.69
Current: 0.63
0.43
1.69
Shiller PE Ratio 22.83
ESRX's Shiller PE Ratio is ranked higher than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.53 vs. ESRX: 22.83 )
Ranked among companies with meaningful Shiller PE Ratio only.
ESRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.5  Med: 43.86 Max: 79.91
Current: 22.83
19.5
79.91
Current Ratio 0.67
ESRX's Current Ratio is ranked lower than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.67 )
Ranked among companies with meaningful Current Ratio only.
ESRX' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 0.9 Max: 5.57
Current: 0.67
0.62
5.57
Quick Ratio 0.55
ESRX's Quick Ratio is ranked lower than
80% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.55 )
Ranked among companies with meaningful Quick Ratio only.
ESRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 0.8 Max: 4.78
Current: 0.55
0.5
4.78
Days Inventory 7.84
ESRX's Days Inventory is ranked higher than
55% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.84 vs. ESRX: 7.84 )
Ranked among companies with meaningful Days Inventory only.
ESRX' s Days Inventory Range Over the Past 10 Years
Min: 3.02  Med: 5.49 Max: 8.16
Current: 7.84
3.02
8.16
Days Sales Outstanding 14.96
ESRX's Days Sales Outstanding is ranked higher than
80% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.58 vs. ESRX: 14.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ESRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.11  Med: 15.16 Max: 24.11
Current: 14.96
14.11
24.11
Days Payable 15.01
ESRX's Days Payable is ranked lower than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 42.32 vs. ESRX: 15.01 )
Ranked among companies with meaningful Days Payable only.
ESRX' s Days Payable Range Over the Past 10 Years
Min: 5.7  Med: 11.91 Max: 15.43
Current: 15.01
5.7
15.43

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 7.90
ESRX's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.50 vs. ESRX: 7.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.4  Med: -0.5 Max: 7.9
Current: 7.9
-14.4
7.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.55
ESRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. ESRX: 0.55 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ESRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.29 Max: 7.15
Current: 0.55
0.55
7.15
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.41
ESRX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
89% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. ESRX: 0.41 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ESRX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.41  Med: 1.72 Max: 2.99
Current: 0.41
0.41
2.99
Price-to-Median-PS-Value 0.76
ESRX's Price-to-Median-PS-Value is ranked higher than
74% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. ESRX: 0.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ESRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.07 Max: 5.1
Current: 0.76
0.54
5.1
Price-to-Peter-Lynch-Fair-Value 0.63
ESRX's Price-to-Peter-Lynch-Fair-Value is ranked higher than
91% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. ESRX: 0.63 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ESRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.6  Med: 1.1 Max: 2.07
Current: 0.63
0.6
2.07
Earnings Yield (Greenblatt) % 9.89
ESRX's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.22 vs. ESRX: 9.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ESRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 6.4 Max: 12.2
Current: 9.89
3.3
12.2
Forward Rate of Return (Yacktman) % 24.73
ESRX's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.01 vs. ESRX: 24.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ESRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 22.2  Med: 24.6 Max: 27.6
Current: 24.73
22.2
27.6

More Statistics

Revenue (TTM) (Mil) $100,064.60
EPS (TTM) $ 7.75
Beta1.00
Volatility23.20%
52-Week Range $55.80 - 85.07
Shares Outstanding (Mil)561.53

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 102,200 140,774
EBIT (Mil $) 6,703 5,895
EBITDA (Mil $) 7,536 6,516
EPS ($) 7.93 9.96
EPS without NRI ($) 7.93 9.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.25%
Dividends per Share ($) 0.38 0.38

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}